Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Pulmonology

Standard of Care Treatment for DAH

At a Glance

The treatment of Diffuse Alveolar Hemorrhage (DAH) involves three main phases: immediate respiratory stabilization, aggressive induction therapy to suppress the immune system and stop bleeding, and long-term maintenance therapy. Medications often include pulse steroids and immunosuppressants.

The treatment of Diffuse Alveolar Hemorrhage (DAH) is a high-stakes race to accomplish two things at once: providing immediate support so you can breathe, and “turning off” the underlying cause of the bleeding [1][2]. Because immune-mediated DAH is often life-threatening, the medical response is usually aggressive and fast.

Phase 1: Stabilization

Before your doctors can address the “why,” they must ensure your body is receiving enough oxygen. This may involve:

  • Supplemental Oxygen: Using nasal tubes or high-flow masks [3].
  • Mechanical Ventilation: If the bleeding is severe, a ventilator may be necessary to breathe for you and allow your lungs to rest [4].
  • ECMO: In very rare, critical cases, an “artificial lung” machine (Extracorporeal Membrane Oxygenation) may be used to oxygenate your blood outside your body [5]. However, because ECMO typically requires blood thinners to run the machine, which can worsen lung bleeding, this is an absolute last resort requiring highly specialized management.

Phase 2: Stopping the Attack (Induction Therapy)

If your DAH is caused by an autoimmune condition, your doctors will use induction therapy—powerful medications designed to rapidly suppress your immune system [1].

  • Pulse Steroids: You will likely receive “pulse” doses of methylprednisolone (an extremely strong intravenous steroid) for 3 to 5 days [6][7]. This acts as a “fire extinguisher” to quickly calm inflammation in the lung capillaries [8].
  • Immunosuppressants: To keep the immune system from restarting the attack, doctors add another potent medication:
    • Rituximab: A targeted therapy that eliminates the B-cells responsible for producing harmful antibodies [9][10].
    • Cyclophosphamide: A traditional, very strong immunosuppressant often used in severe cases [1][10].
  • Avacopan: This is a newer “adjunct” (add-on) therapy specifically for ANCA-associated vasculitis. It targets a specific part of the immune system (the complement system), allowing doctors to use significantly lower doses of steroids, which reduces the risk of long-term steroid side effects [11][12].

The Plasma Exchange (PLEX) Controversy

Plasma Exchange (PLEX) is a procedure where your blood is filtered to remove harmful antibodies [13]. Its use has become a subject of intense medical debate recently due to new research.

ANCA-Associated Vasculitis (AAV)

For years, PLEX was standard for severe AAV. However, a major study called the PEXIVAS trial changed the landscape [14]. The trial found that for patients with AAV, adding PLEX to standard drug therapy did not significantly reduce the risk of death or permanent kidney failure [14][15]. Furthermore, PLEX was linked to a higher risk of serious infections [16]. As a result, many experts now discourage its routine use for AAV unless the case is exceptionally severe or refractory [17][18].

Anti-GBM Disease (Goodpasture’s)

In contrast, PLEX remains the absolute standard of care for Anti-GBM disease [13][19]. In this condition, the antibodies are so aggressive and damaging to the lungs and kidneys that removing them immediately via PLEX is critical for survival and organ recovery [20][21].

Phase 3: Long-Term Maintenance

Once the initial bleeding stops (remission), you will transition to maintenance therapy [11]. Your doctors will slowly taper (reduce) your high-dose steroids over several months to minimize side effects, replacing them with milder oral immunosuppressants to prevent the DAH from returning [22][23].

Common questions in this guide

What is the first step in treating Diffuse Alveolar Hemorrhage?
The immediate priority in treating DAH is stabilization to ensure your body receives enough oxygen. This may involve supplemental oxygen, a mechanical ventilator, or in rare cases, an artificial lung machine called ECMO.
What is induction therapy for DAH?
Induction therapy involves using powerful medications, like pulse steroids and immunosuppressants, to rapidly stop your immune system from attacking your lungs. This acts quickly to calm inflammation and stop the bleeding.
Will I need plasma exchange (PLEX) for DAH?
The need for plasma exchange depends on the underlying cause of your DAH. It is the absolute standard of care for Anti-GBM disease, but recent studies suggest it should not be routinely used for ANCA-associated vasculitis unless the case is exceptionally severe.
What is Avacopan and how is it used?
Avacopan is an add-on therapy for patients whose DAH is caused by ANCA-associated vasculitis. It targets a specific part of the immune system, allowing doctors to use lower doses of steroids and reducing the risk of long-term side effects.
What happens after the initial DAH bleeding stops?
Once the bleeding is controlled, you will transition to long-term maintenance therapy. Doctors will slowly reduce your high-dose steroids and replace them with milder oral immunosuppressants to prevent the bleeding from returning.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific timeline for my 'pulse' steroid treatment, and when will we transition to a lower dose?
  2. 2.Based on the PEXIVAS trial results, why is plasma exchange being recommended (or not recommended) in my specific case?
  3. 3.Am I a candidate for Avacopan to help reduce the amount of steroids I need?
  4. 4.Which induction medication—Rituximab or Cyclophosphamide—is better suited for my underlying diagnosis and long-term health?
  5. 5.How are we monitoring for potential side effects, like infection or liver enzyme changes, during this intensive treatment phase?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies.

    Al-Adhoubi NK, Bystrom J

    Lupus 2020; (29(4)):355-363 doi:10.1177/0961203320903798.

    PMID: 32036761
  2. 2

    [Diffuse alveolar hemorrhage - acute, life-threatening situation in rheumatology].

    Bradna P, Maňák J, Soukup T, et al.

    Vnitrni lekarstvi 2018; (64(2)):169-172.

    PMID: 29595282
  3. 3

    Connective Tissue Disorder-Induced Diffuse Alveolar Hemorrhage: A Comprehensive Review with an Emphasis on Airway and Respiratory Management.

    Mudgal M, Balaji S, Gajendiran AP, et al.

    Life (Basel, Switzerland) 2025; (15(5)) doi:10.3390/life15050793.

    PMID: 40430219
  4. 4

    Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS).

    Fussner LA, Flores-Suárez LF, Cartin-Ceba R, et al.

    American journal of respiratory and critical care medicine 2024; (209(9)):1141-1151 doi:10.1164/rccm.202308-1426OC.

    PMID: 38346237
  5. 5

    Venovenous Extracorporeal Membrane Oxygenation in Diffuse Alveolar Hemorrhage Secondary to Anti-neutrophil Cytoplasmic Autoantibody-associated Vasculitis: Starting without Systemic Anticoagulation.

    Ohta S, Matsuyoshi T, Kaneko H, et al.

    Internal medicine (Tokyo, Japan) 2022; (61(23)):3569-3573 doi:10.2169/internalmedicine.9472-22.

    PMID: 35569985
  6. 6

    A 32-year-old man with hypoxemia and bilateral upper-lobe predominant ground-glass infiltrates on chest imaging.

    Helgeson SA, Heckman AJ, McCain JD, et al.

    Oxford medical case reports 2018; (2018(10)):omy072 doi:10.1093/omcr/omy072.

    PMID: 30302263
  7. 7

    Diffuse Alveolar Hemorrhage Developing Immediately after Immunosuppressive Treatments in a Patient with Granulomatosis with Polyangiitis Who Had Pulmonary Nodules.

    Watanabe C, Fukui S, Iwamoto N, et al.

    Internal medicine (Tokyo, Japan) 2018; (57(3)):417-421 doi:10.2169/internalmedicine.9188-17.

    PMID: 29093401
  8. 8

    Respiratory infection induced episode of alveolar hemorrhage (RIIEAH) in the pediatric diffuse alveolar hemorrhage: a retrospective single-center study.

    Wei Q, Chen X, Li Y, et al.

    BMC pediatrics 2025; (25(1)):633 doi:10.1186/s12887-025-05958-1.

    PMID: 40830444
  9. 9

    CD20 monoclonal antibody‑rituximab for the treatment of diffuse alveolar hemorrhage in children (Review).

    Zhang X, Wu X, Li Y, Nong G

    Molecular medicine reports 2026; (33(4)).

    PMID: 41645750
  10. 10

    Diffuse Alveolar Hemorrhage in Autoimmune Diseases.

    Martínez-Martínez MU, Oostdam DAH, Abud-Mendoza C

    Current rheumatology reports 2017; (19(5)):27 doi:10.1007/s11926-017-0651-y.

    PMID: 28397125
  11. 11

    Avacopan for the Treatment of ANCA-Associated Vasculitis.

    Jayne DRW, Merkel PA, Schall TJ, et al.

    The New England journal of medicine 2021; (384(7)):599-609 doi:10.1056/NEJMoa2023386.

    PMID: 33596356
  12. 12

    Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence.

    Jayne D

    Rheumatology (Oxford, England) 2026; (65(Supplement_1)):i20-i26 doi:10.1093/rheumatology/keaf581.

    PMID: 41183103
  13. 13

    Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients.

    Liu Y, Wu Y, Wei W, et al.

    Renal failure 2024; (46(2)):2400539 doi:10.1080/0886022X.2024.2400539.

    PMID: 39258391
  14. 14

    Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

    Walsh M, Merkel PA, Peh CA, et al.

    The New England journal of medicine 2020; (382(7)):622-631 doi:10.1056/NEJMoa1803537.

    PMID: 32053298
  15. 15

    PEXIVAS challenges current ANCA-associated vasculitis therapy.

    Morris A, Geetha D

    Nature reviews. Nephrology 2020; (16(7)):373-374 doi:10.1038/s41581-020-0269-6.

    PMID: 32203311
  16. 16

    Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 1: plasma exchange should not be used indiscriminately.

    Walsh M

    Rheumatology (Oxford, England) 2025; (64(Supplement_1)):i64-i67 doi:10.1093/rheumatology/keaf011.

    PMID: 40071428
  17. 17

    The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.

    Walsh M, Collister D, Zeng L, et al.

    BMJ (Clinical research ed.) 2022; (376()):e064604 doi:10.1136/bmj-2021-064604.

    PMID: 35217545
  18. 18

    Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges.

    Nezam D, Porcher R, Grolleau F, et al.

    Journal of the American Society of Nephrology : JASN 2022; (33(3)):628-637 doi:10.1681/ASN.2021060771.

    PMID: 35074934
  19. 19

    Rapidly Progressive Glomerulonephritis.

    Koirala A, Sharma PD, Jhaveri KD, et al.

    Advances in kidney disease and health 2024; (31(6)):485-495 doi:10.1053/j.akdh.2024.08.006.

    PMID: 39577882
  20. 20

    Concurrent anti-glomerular basement membrane disease and membranous nephropathy: a case report.

    Li LL, Niu PY, Li N, et al.

    Frontiers in medicine 2025; (12()):1654203 doi:10.3389/fmed.2025.1654203.

    PMID: 41262443
  21. 21

    Goodpasture's Syndrome with Negative Anti-glomerular Basement Membrane Antibodies.

    Vries TB, Boerma S, Doornebal J, et al.

    European journal of case reports in internal medicine 2017; (4(8)):000687 doi:10.12890/2017_000687.

    PMID: 30755961
  22. 22

    Treatment With Avacopan in Patients With Respiratory Tract Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Specks U, Spiera RF, Fussner LA, et al.

    ACR open rheumatology 2025; (7(1)):e11795 doi:10.1002/acr2.11795.

    PMID: 39854178
  23. 23

    Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.

    Cortazar FB, Niles JL, Jayne DRW, et al.

    Kidney international reports 2023; (8(4)):860-870 doi:10.1016/j.ekir.2023.01.039.

    PMID: 37069984

This page explains standard treatments for Diffuse Alveolar Hemorrhage for educational purposes. Always consult your pulmonologist or critical care team for specific medical advice and emergency care.

Get notified when new evidence is published on Diffuse alveolar hemorrhage.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.